Market Place
Sourcing Support
All News #Library
Biotech
Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+
06 Sep 2025 //
BIOSPACE
Hengrui’s GLP-1/GIP Agonist Reports 18% Weight Loss in Phase 3
16 Jul 2025 //
FIERCE BIOTECH
IDEAYA Biosciences Announces FDA IND-Clearance for IDE849
06 May 2025 //
PR NEWSWIRE
Merck Commits Nearly $2B for Oral Lipid-Lowering Drug from Chinese Biotech
26 Mar 2025 //
BIOSPACE
IDEAYA snags second ADC in tie-up with Hengrui worth $1B
30 Dec 2024 //
PRESS RELEASE
Investors put $400M into biotech licensing obesity drugs from China
17 May 2024 //
BIOPHARMADIVE
Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab
17 Oct 2023 //
GLOBENEWSWIRE
Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR
10 Apr 2023 //
PRESS RELEASE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.